BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 32589269)

  • 21. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.
    Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Grønbæk H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; van der Poorten D; George J; Eslam M;
    Nat Commun; 2016 Sep; 7():12757. PubMed ID: 27630043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of MBOAT7 gene variant with plasma ALT levels in children: the PANIC study.
    Viitasalo A; Eloranta AM; Atalay M; Romeo S; Pihlajamäki J; Lakka TA
    Pediatr Res; 2016 Nov; 80(5):651-655. PubMed ID: 27411039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants.
    Liu Z; Suo C; Shi O; Lin C; Zhao R; Yuan H; Jin L; Zhang T; Chen X
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e855-e875. PubMed ID: 33387670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity-linked suppression of membrane-bound
    Helsley RN; Varadharajan V; Brown AL; Gromovsky AD; Schugar RC; Ramachandiran I; Fung K; Kabbany MN; Banerjee R; Neumann CK; Finney C; Pathak P; Orabi D; Osborn LJ; Massey W; Zhang R; Kadam A; Sansbury BE; Pan C; Sacks J; Lee RG; Crooke RM; Graham MJ; Lemieux ME; Gogonea V; Kirwan JP; Allende DS; Civelek M; Fox PL; Rudel LL; Lusis AJ; Spite M; Brown JM
    Elife; 2019 Oct; 8():. PubMed ID: 31621579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
    Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
    Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
    Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
    J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease.
    Sookoian S; Flichman D; Garaycoechea ME; Gazzi C; Martino JS; Castaño GO; Pirola CJ
    Sci Rep; 2018 Mar; 8(1):5097. PubMed ID: 29572551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MBOAT7 in liver and extrahepatic diseases.
    Caddeo A; Spagnuolo R; Maurotti S
    Liver Int; 2023 Nov; 43(11):2351-2364. PubMed ID: 37605540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of alanine aminotransferase levels and a histological diagnosis of steatohepatitis with ultrasound-diagnosed metabolic-associated fatty liver disease in patients from a centre in Nigeria.
    Kolawole OJ; Oje MM; Betiku OA; Ijarotimi O; Adekanle O; Ndububa DA
    BMC Gastroenterol; 2024 May; 24(1):147. PubMed ID: 38724942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent.
    Palmer ND; Musani SK; Yerges-Armstrong LM; Feitosa MF; Bielak LF; Hernaez R; Kahali B; Carr JJ; Harris TB; Jhun MA; Kardia SL; Langefeld CD; Mosley TH; Norris JM; Smith AV; Taylor HA; Wagenknecht LE; Liu J; Borecki IB; Peyser PA; Speliotes EK
    Hepatology; 2013 Sep; 58(3):966-75. PubMed ID: 23564467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of MBOAT7 polymorphism and steatosis on liver function assessed by methacetin breath test.
    Di Ciaula A; Bonfrate L; Shanmugam H; Weber SN; Krawczyk M; Portincasa P
    Eur J Clin Invest; 2023 Aug; 53(8):e14003. PubMed ID: 37029745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.
    Luukkonen PK; Zhou Y; Hyötyläinen T; Leivonen M; Arola J; Orho-Melander M; Orešič M; Yki-Järvinen H
    J Hepatol; 2016 Dec; 65(6):1263-1265. PubMed ID: 27520876
    [No Abstract]   [Full Text] [Related]  

  • 38. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Basyte-Bacevice V; Skieceviciene J; Valantiene I; Sumskiene J; Petrenkiene V; Kondrackiene J; Petrauskas D; Lammert F; Kupcinskas J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    Bianco C; Jamialahmadi O; Pelusi S; Baselli G; Dongiovanni P; Zanoni I; Santoro L; Maier S; Liguori A; Meroni M; Borroni V; D'Ambrosio R; Spagnuolo R; Alisi A; Federico A; Bugianesi E; Petta S; Miele L; Vespasiani-Gentilucci U; Anstee QM; Stickel F; Hampe J; Fischer J; Berg T; Fracanzani AL; Soardo G; Reeves H; Prati D; Romeo S; Valenti L
    J Hepatol; 2021 Apr; 74(4):775-782. PubMed ID: 33248170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.